High sugar-sweetened beverage (SSB) consumption is a growing public health concern linked to obesity and chronic diseases. This study analyzed global trends and disparities in high SSB consumption among young adults aged 15–39 years from 1990 to 2021, using data from the Global Burden of Disease (GBD) Study 2021. High SSB consumption was defined as intake of beverages with ≥ 50 kcal per 226.8-gram serving, excluding 100% fruit and vegetable juices. We calculated the prevalence and estimated annual percentage change (EAPC) to track temporal trends and identify significant shifts. The global prevalence of high SSB consumption among young adults increased from 6.58% in 1990 to 11.13% in 2021. Females consistently exhibited a higher prevalence compared to males. In 2021, high SDI countries had the highest prevalence (30.83%), while low SDI countries had the lowest prevalence (2.91%). High-middle SDI countries experienced the fastest increase in SSB consumption, with an EAPC of 2.99%. A strong positive correlation was found between national SDI and SSB prevalence in 2021 (ρ = 0.78, p < 2.2e-16). Rising global SSB consumption among young adults highlights the need for targeted public health interventions, especially considering disparities across gender, SDI levels, and regions.
Background Adolescent high body mass index (BMI) is a growing global health problem. This study analyzes global, regional, and national prevalence and trends of high BMI among adolescents (aged 10–19 years) from 1990 to 2021, investigates disparities by sex, country, and socio-demographic index (SDI), and projects prevalence to 2030. Methods This study analyzed Global Burden of Disease (GBD) study 2021 data. Prevalence and trends of high BMI among adolescents were stratified by sex, SDI, and region. Estimated annual percentage change (EAPC), joinpoint regression, and Bayesian age-period-cohort (BAPC) analysis were used to quantify trends and project prevalence to 2030. Results Global adolescent high BMI prevalence has increased from 8.36% (1990) to 17.64% (2021), with females having a slightly higher prevalence than males. Marked disparities are observed across SDI levels; high SDI countries have the highest prevalence, but middle SDI countries are experiencing the fastest increases. Substantial geographic variations are also evident, with particularly rapid increases in some regions, such as the Pacific Island nations, and slower growth or declines in others, such as parts of East Asia. The BAPC model projects a continued rise in global high BMI prevalence up to 2030, with considerable variation across individual countries. Conclusions The global rise of high BMI among adolescents, coupled with projections of continued increases, presents a pressing public health concern. The observed disparities across SDI levels and geographic regions necessitate tailored interventions to address this growing epidemic effectively.
Background. Heart failure (HF) is a common cardiovascular disease, which is related to systemic inflammation for decades. Fibrinogen (FIB) is a sign of thrombosis and inflammation, which is associated with the prognosis of many diseases. Nevertheless, the role of fibrinogen level in the prognosis of critically ill patients with acute exacerbation of chronic heart failure is unclear. Methods. The data are from the Medical Information Mart for Intensive Care III (MIMIC III) database, which is a freely accessible critical care database. The primary outcome in our study was 90-day mortality. The prognostic value of fibrinogen was analyzed with receiver operating characteristic (ROC) curve analysis, Kaplan-Meier curve, and Cox model. Results. A total of 554 patients were included. Patients were divided into two groups, low fibrinogen level (284mg/dl) and high fibrinogen level (284mg/dl), through the cut-off value of the ROC curve. The area under the ROC curve of fibrinogen for predicting 90-day mortality was 0.65 (95 CI: 0.590.70). In the unadjusted Cox model, compared with the low fibrinogen level (284mg/dl), the 90-day mortality of the hazard ratio (HR) with 95 confidence intervals (CI) of the high fibrinogen level is 3.33 (95 CI 2.15-5.15). In different multivariable Cox models, compared with the low fibrinogen level (284mg/dl), the 90-day mortality of the hazard ratio of the high fibrinogen level is from 2.83 to 3.13. In subgroup analyses, significant interactions were observed only in age, chronic kidney disease (CKD), and APS III scores. Conclusion. Our data suggest that high fibrinogen levels (284mg/dl) independently predict mortality in critically ill patients with acute exacerbation of chronic heart failure. Our findings need to be further validated by large prospective studies and longer follow-up time.
BACKGROUND:Many heart failure (HF) cases are caused by idiopathic dilated cardiomyopathy (iDCM). This study explored the mechanisms of the development and progression of HF caused by iDCM. MATERIAL AND METHODS:The gene expression profiles of 102 samp...
3 December 2020 in Immunity, Inflammation and Disease
Background: Nucleotide‐binding oligomerization domain‐like receptor family pyrin domain containing 3 (NLRP3) inflammasomes are the most important factors in ventricular arrhythmia associated with heart failure (VA‐HF). However, how the relationship between lncRNA and NLRP3 inflammasomes is regulated in VA‐HF has not been investigated in detail. Thus, we aimed to determine the effects of SOX2‐overlapping transcripts (SOX2‐OT) by targeting NLRP3 in rats with VA‐HF.Methods: We established rats (SPF, male, weight: 240 ± 10 g) with VA‐HF by aortic coarctation and constant‐current stimulation, then injected them with small interfering SOX2‐OT and anti‐miR‐2355‐3p. Six weeks later, SOX2‐OT and miR‐2355‐3p expression was measured using the quantitative reverse transcriptase‐polymerase chain reaction and NLRP3, ASC, caspase‐1, IL‐1β, and TGF‐β1 expression were measured by Western blot analysis; the ventricular chambers were histopathologically analyzed by staining with hematoxylin and eosin, Masson trichrome, and Picro Sirius Red and reactive oxygen species (ROS) levels were assessed by flow cytometry. The targeting relationship between miR‐2355‐3p and SOX2‐OT or NLRP3 was verified using dual‐luciferase reporter gene assays.Results: The expression of SOX2‐OT and levels of NLRP3 inflammasomes gradually increased in normal rats, and in those with heart failure and with VA‐HF. Silencing SOX2‐OT expression inhibited NLRP3, ASC, caspase‐1, IL‐1β, and TGF‐β1 expression and ROS production, reduced the degrees of cardiomyocyte necrosis and fibrosis and alleviated cardiac dysfunction in rats with VA‐HF. MicroR‐2355‐3p can bind the SOX2‐OT and the 3′‐untranslated region of NLRP3. Inhibiting miR‐2355‐3p reversed the effect of SOX2‐OT in rats with VA‐HF.Conclusions: Silencing SOX2‐OT alleviated cardiac dysfunction in rats by reducing the activation of NLRP3 inflammasomes via regulating miR‐2355‐3p.
2 June 2021 in Journal of Interventional Cardiology
Background. High power shorter duration (HPSD) ablation may lead to safe and rapid lesion formation. However, the optimal radio frequency power to achieve the desired ablation index (AI) or lesion size index (LSI) is insubstantial. This analysis aimed to appraise the clinical safety and efficacy of HPSD guided by AI or LSI (HPSD-AI or LSI) in patients with atrial fibrillation (AF). Methods. The Medline, PubMed, Embase, Web of Science, and the Cochrane Library databases from inception to November 2020 were searched for studies comparing HPSD-AI or LSI and low power longer duration (LPLD) ablation. Results. Seven trials with 1013 patients were included in the analysis. The analyses verified that HPSD-AI or LSI revealed benefits of first-pass pulmonary vein isolation (PVI) (RR: 1.28; 95 CI: 1.051.56, P0.01) and acute pulmonary vein reconnection (PVR) (RR: 0.65; 95 CI: 0.480.88, P0.005) compared with LPLD. HPSD-AI or LSI showed higher freedom from atrial tachyarrhythmia (AT) (RR1.32, 95 CI: 1.141.53, P0.0002) in the subgroup analysis of studies with PVI (with or without additional ablation beyond PVI). HPSD-AI or LSI could short procedural time (WMD: 22.81; 95 CI, 35.03 to 10.60, P0.0003), ablation time (WMD: 10.80; 95 CI: 13.14 to 8.46, P.00001), and fluoroscopy time (WMD: 7.71; 95 CI: 13.71 to 1.71, P0.01). Major complications and esophageal lesion in HPSD-AI or LSI group were no more than LDLP group (RR: 0.58; 95 CI: 0.201.69, P0.32) and (RR: 0.84; 95 CI: 0.431.61, P0.59). Conclusions. HPSD-AI or LSI was efficient for treating AF with shorting procedural, ablation, and fluoroscopy time, higher first-pass PVI, and reducing acute PVR and may increase freedom from AT for patients with additional ablation beyond PVI compared with LPLD. Moreover, complications and esophageal lesion were low and no different between two groups.